The cost-effectiveness of @entity1443 , NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic XXXX .

@entity1 @entity13586 @entity12698 @entity626 @entity571 @entity5018 @entity396 @entity158 @entity1443
OBJECTIVE: The objective of this study was to conduct an economic evaluation of @entity13586 and @entity12698 compared with high-dose @entity1443 or @entity5018 with and without @entity396 for @entity1 with symptomatic @entity626 ( @entity571 ). METHODS: A decision analysis model was designed over 6 months using two measures of effectiveness: 1) number of upper gastrointestinal (GI) adverse events averted; and 2) number of @entity1 who achieved perceptible @entity158 relief. Separate analyses were conducted for all @entity1 and for those who did not respond to @entity1443 . Outcome probabilities were obtained from a comprehensive review of randomized controlled trials and observational studies. Costs were derived from actual resource utilization of @entity571 @entity1 . RESULTS: In terms of averting GI events, @entity1443 dominates the other options for an average risk @entity1 population. For @entity1 who did not respond to @entity1443 , @entity13586 had the lowest incremental cost-effectiveness ratio (ICER) per GI event avoided (32,000 US dollars) relative to @entity5018 . In terms of @entity158 control, @entity5018 had an ICER of 610.77 US dollars per additional @entity1 achieving minimal perceptible clinical improvement (MPCI) relative to @entity1443 , while @entity13586 had an ICER of 12,000 US dollars relative to @entity5018 . For @entity1 who did not respond to @entity1443 and who are at high risk of developing an adverse GI event, @entity13586 dominates @entity5018 as the preferred alternative for both measures of effectiveness. One-way, two-way, and probabilistic sensitivity analyses established that these results were generally robust. CONCLUSIONS: Our results suggest that for average-risk knee @entity571 @entity1 , @entity1443 dominates the other therapies in terms of cost per GI event averted. In terms of @entity158 relief, cost-effectiveness acceptability curves indicate that if one @entity158 relief below 275 US dollars per @entity1 achieving MPCI, @entity1443 is the therapy most likely to be optimal; between 275 US dollars and 14,150 US dollars, @entity5018 is most likely to be optimal; and above 14,150 US dollars, @entity13586 is most likely to be optimal.
